Antiviral therapy: old and current issues

Int J Antimicrob Agents. 2012 Aug;40(2):95-102. doi: 10.1016/j.ijantimicag.2012.04.005. Epub 2012 Jun 21.

Abstract

Many antiviral drugs are currently approved and formally licensed for clinical use in the treatment of viral infections caused by human immunodeficiency virus, herpes simplex viruses, varicella-zoster virus, respiratory syncytial virus, cytomegalovirus, hepatitis B virus, hepatitis C virus or influenza virus. Recent decades have seen major advances in our knowledge of the natural history and pathogenesis of viral diseases as well as ongoing developments and improvements in antiviral therapy. However, research is far from complete and indeed previously unknown and unexpected issues are currently arising. This review aims to discuss some of these issues in the belief that they should be carefully addressed to enhance the management of patients with viral infections.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antiviral Agents / administration & dosage
  • Antiviral Agents / classification
  • Antiviral Agents / therapeutic use*
  • Drug Monitoring
  • Drug Resistance, Viral*
  • HIV / genetics
  • HIV / pathogenicity
  • HIV / physiology
  • Hepatitis Viruses / genetics
  • Hepatitis Viruses / pathogenicity
  • Hepatitis Viruses / physiology
  • Humans
  • Nucleic Acid Synthesis Inhibitors / administration & dosage
  • Nucleic Acid Synthesis Inhibitors / therapeutic use
  • Protease Inhibitors / administration & dosage
  • Protease Inhibitors / therapeutic use
  • Virus Diseases / drug therapy*
  • Virus Diseases / virology
  • Virus Integration / drug effects
  • Virus Internalization / drug effects
  • Virus Release / drug effects
  • Virus Replication / drug effects
  • Virus Uncoating / drug effects

Substances

  • Antiviral Agents
  • Nucleic Acid Synthesis Inhibitors
  • Protease Inhibitors